Surmodics | SRDX - Gross Profit On Sales


Surmodics reported $-11.54M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.





Gross Profit On Sales Change Date
Abbott USD 6.54B 625M Dec/2025
Align Technology USD 683.59M 44.39M Dec/2025
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Artivion USD 73.14M 1.25M Dec/2025
Baxter International USD 577M 373M Dec/2025
Boston Scientific USD 3.68B 136M Dec/2025
EDAP TMS EUR 5.97M 850K Sep/2025
Edwards Lifesciences USD 1.23B 18.7M Dec/2025
Haemonetics USD 202.39M 7.64M Dec/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
J&J USD 16.6B 118M Dec/2025
Merit Medical Systems USD 195.35M 8.94M Dec/2025
Mesa Laboratories USD 39.75M 4.3M Dec/2024
Nektar Therapeutics USD 13.75M 650K Jun/2024
Option Care Health USD 282.9M 10M Dec/2025
Stryker USD 4.49B 633M Dec/2025
Surmodics USD -11.54M 3.99M Sep/2024
Trinity Biotech USD 6.47M 1.59M Sep/2025